Exploring the role and therapeutic potential of RNA N6-methyladenosine modification in abortion disease pathology: a comprehensive review

Read full text
Authors: Zhuo Chang, Lu-Hao Li, Liang-Zhen Lv, Zhaodi Wang, Qingyi Wang, Hui Zhu, Bei Jiang, Xue-Ming Zhou, Yapeng Han, Xue Pan, Li Ren, Sen Cheng
+1 more Z. H. Lei
Cited by: 1
References: 118

Abstract

Recurrent spontaneous abortion (RSA), defined as two or more consecutive pregnancy losses, affects 1%-5% of couples and poses a significant challenge to reproductive health. Despite its prevalence, the underlying etiology remains elusive in approximately half of all cases, hindering the development of targeted therapies. The emerging field of epitranscriptomics, particularly the dynamic and reversible N6-methyladenosine (m6A) RNA modification, offers a novel lens through which to investigate the complex gene-environment interactions underlying RSA. This review systematically synthesizes current knowledge on the pivotal roles of m6A modification in key processes essential for a successful pregnancy: gametogenesis and early embryo quality, placental development and function, and the establishment of immune tolerance at the maternal-fetal interface. We critically evaluate the direct and indirect evidence linking dysregulation of specific m6A regulators to the pathophysiology of RSA, drawing from human tissue studies, RSA animal models, and insights extrapolated from related fields.Furthermore, we discuss the translational potential and considerable challenges of targeting the m6A machinery for therapeutic intervention in RSA. This review aims not only to summarize the current landscape but also to provide a critical framework to guide future mechanistic and clinical research in this promising area.

Fields of Study & Subjects

RNA modifications and cancer Metalloenzymes and iron-sulfur proteins Chromatin Remodeling and Cancer

Publication details

Journal / source
Frontiers in Genetics
Publisher
Frontiers Media SA
Volume
16
Pages
1720842–1720842
Publication date
6 January 2026
Language
EN